Cited by 274Drug Transport and Resistance MechanismsPharmacogenetics and Drug MetabolismAntibiotic Resistance in Bacteria

Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases

Open access
Chen, Zhe‐Sheng, Tiwari, Amit K.·2011·The FEBS Journal

Abstract

The ATP‐binding cassette (ABC) transporters are a superfamily of membrane proteins that are best known for their ability to transport a wide variety of exogenous and endogenous substances across membranes against a concentration gradient via ATP hydrolysis. There are seven subfamilies of human ABC transporters, one of the largest being the ‘C’ subfamily (gene symbol ABCC ). Nine ABCC subfamily members, the so‐called multidrug resistance proteins (MRPs) 1–9, have been implicated in mediating multidrug resistance in tumor cells to varying degrees as the efflux extrude chemotherapeutic compounds (or their metabolites) from malignant cells. Some of the MRPs are also known to either influence drug disposition in normal tissues or modulate the elimination of drugs (or their metabolites) via hepatobiliary or renal excretory pathways. In addition, the cellular efflux of physiologically important organic anions such as leukotriene C 4 and cAMP is mediated by one or more of the MRPs. Finally, mutations in several MRPs are associated with human genetic disorders. In this minireview, the current biochemical and physiological knowledge of MRP1–MRP9 in cancer chemotherapy and human genetic disease is summarized. The mutations in MRP2/ABCC2 leading to conjugated hyperbilirubinemia (Dubin–Johnson syndrome) and in MRP6/ABCC6 leading to the connective tissue disorder Pseudoxanthoma elasticum are also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-4658.2011.08235.x

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Another disadvantage of targeting the active site of kinases is that those inhibitors are highly susceptible to resistance arising from mutations in the catalytic domain, such as drug resistance to imatinib in chronic myeloid leukemia patients.

    “Another disadvantage of targeting the active site of kinases is that those inhibitors are highly susceptible to resistance arising from mutations in the catalytic domain, such as drug resistance to imatinib in the case of chronic myeloid leukemia patients [4, 105].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, Z., & Tiwari, A. K.
Affiliations
St. John's University (US)
Venue
The FEBS Journal
Publisher
Wiley
Published
2011-08
Volume
278
Issue
18
Pages
3226-3245
ISSN
  • 1742-464X (ISSN-L)
  • 1742-4658
OpenAlex
W1754555893
Cited by
274
References
195
Citations by year
2026: 8 · 2025: 16 · 2024: 7 · 2023: 10 · 2022: 11 · 2021: 16 · 2020: 19 · 2019: 25 · 2018: 15 · 2017: 18 · 2016: 17 · 2015: 23 · 2014: 30 · 2013: 32 · 2012: 23
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • FEBS Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R15CA143701)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
Keywords
multidrug resistance protein, ABCC transporters, ABC transporters, multidrug resistance, cancer chemotherapy, drug efflux, drug disposition, organic anion transport, leukotriene C4, cyclic AMP, Dubin-Johnson syndrome, pseudoxanthoma elasticum, genetic disorders
MeSH terms
Multidrug Resistance-Associated Protein 2, Animals, Humans, Mutation, Neoplasms, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Protein Isoforms, ATP-Binding Cassette, Sub-Family C Proteins, Genetic Diseases, Inborn

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review